SCHEMBL5136852

SCHEMBL5136852

CCCCN(Cc1ccc(OC)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
GAA P10253 2/20 0.46
TSHR P16473 2/20 0.46
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HSD17B10 Q99714 1/20 0.43
ATP4A P20648 4/20 0.42
ATP4B P51164 4/20 0.42
C5AR1 P21730 1/20 0.40
DRD2 P14416 2/20 0.39
DRD3 P35462 2/20 0.39
BCHE P06276 3/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CNR2 P34972 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
CRHR1 P34998 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137164 0.96 C5AR1 (0.44) ALDH1A1KDM4EGAATSHRLMNA
SCHEMBL5135871 0.95 ATP4A (0.44) ALDH1A1KDM4EGAATSHRLMNA
SCHEMBL5075063 0.95 TP53 (0.42) ALDH1A1KDM4EGAATSHRLMNA
SCHEMBL5136763 0.92 KDM4E (0.43) ALDH1A1KDM4EGAATSHRLMNA
SCHEMBL5136000 0.92 ATP4A (0.42) ALDH1A1KDM4EGAATSHRLMNA
SCHEMBL5075068 0.92 ATP4A (0.52) ATP4AATP4BDRD2DRD3PPARG
SCHEMBL5144432 0.92 C5AR1 (0.44) ALDH1A1KDM4EGAATSHRLMNA
SCHEMBL5070096 0.92 ATP4A (0.50) ATP4AATP4BDRD2DRD3
SCHEMBL5137336 0.91 ATP4A (0.46) ATP4AATP4BC5AR1DRD2DRD3
SCHEMBL651365 0.91 C5AR1 (0.46) ALDH1A1KDM4EGAATSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed